Summary
New agents with increased activity and/or reduced toxicity are needed for the treatment of advanced breast cancer. The anthracene derivatives mitoxantrone and bisantrene had significant activity and acceptable toxicity in phase II trials. In an ongoing phase III trial we have now randomized 150 patients with advanced breast cancer to either doxorubicin (60 mg/m2), mitoxantrone (14 mg/m2) or bisantrene (260 mg/m2) i.v. q 3 weeks with re-randomization for cross-over at the time of progression to determine the relative efficacy and toxicity of these three agents. To be eligible, patients must have had only one previous chemotherapy regimen. ER positive patients must have failed endocrine therapy. Patients with CHF or severe cardiac disease were ineligible. In this preliminary evaluation, 117 patients are evaluable for response and 110 for toxicity. Median age for all patients is 58 years (range 26–78). The majority (86%) are postmenopausal. Fifty-nine percent of the patients have visceral dominant disease. Estrogen receptor is positive in 37%, negative in 39% and unknown in 24% of patients. Median performance status (SWOG) is 1, range 0–2. Objective responses have been observed on each arm (doxorubicin 9/35, mitoxantrone 6/38, bisantrene 6/44). Thirty-two patients are evaluable for cross-over response (doxorubicin 2/13, mitoxantrone 1/11, bisantrene 0/8). The predominant toxicity is leukopenia with a nadir WBC count <2000 in 45% of all courses administered. Leukopenia is similar with the three drugs. Significant nausea, vomiting and alopecia are common with doxorubicin and uncommon with the other agents. Congestive heart failure has been observed in one patient (doxorubicin). Definitive conclusions regarding the efficacy and toxicity of these agents await the completion of this trial.
Similar content being viewed by others
References
Carter SK: Chemotherapy of breast cancer; current status. In Heuson, Mattheien and Rozencweig (eds.): Breast Cancer Trends in Research and Treatment. Raven Press, New York, 1976, pp 193–215
Carbone PP, Tormey DC: Combination chemotherapy for advanced disease. In WL McGuire (ed.): Breast Cancer: Advances in Research and Treatment. Plenum, New York, 1977, pp 165–215
Tormey DC: Adriamycin in breast cancer: an overview of studies. Cancer Chemother Rep (Part 3) 6:319–327, 1975
Johnson RK, Zee-Cheng RK-Y, Lee WW, Actor EM, Henry DW, Cheng CC: Experimental antitumor activity of aminoanthraquinones. Cancer Treat Rep 63:425–439, 1979
Wallace RE, Murdock KC, Anzier RB, Durr FE: Activity of a novel anthracenedione, 1, 4-dihydroxy-5, 8-bis((2-((2- hydroxyethyl)amino)ethyl)amino-9, 10-anthracenedione dihydrochloride, against experimental tumors in mice. Cancer Res 39:1570–1574, 1979
Von Hoff DD, Coltmann CA, Forseth B: Activity of mitoxantrone in a human tumor cloning system. Cancer Res 41:1853–1855, 1981
Yap HY, Blumenschein GR, Schell FC, Buzdar AV, Valdivieso M, Bodey GP: A phase II study of dihydroxyanthracenedione (DHAD) (NSC-301739) in metastatic breast cancer. Ann Int Med 95:694–696, 1981
Nagel GA: Promising new anticancer agents (Abstract). Section 84. 12th Intern Cong Chemother, Florence, Italy, 1981
Coleman RE, Maisey MN, Knight RK, Rubens RD: Mitoxantrone in advanced breast cancer; a phase II study with special attention to cardiotoxicity. Eur J Cancer Clin Oncol 20:771–776, 1984
Citarella RV, Wallace RE, Murdock KC, Anzier RB, Durr FC: Antitumor activity of CL216,942: 9, 10-anthracenedicarboxaldehyde bis ((4, 5 dihydro-1 H-imidazol-2-yl)- hydrazone) dihydrochloride (Abstract 23). Abstracts of the 20th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1980.
Von Hoff DD, Coltman CA Jr, Forseth B: Activity of 9, 10-anthracenedicarboxaldehyde bis ((4,5 dihydro-1Himidazol-2-yl) hydrazone) dihydrochloride (CL 216, 942) in a human tumor cloning system: leads for phase II trials in man. Cancer Chemother Pharmacol 6:141–144, 1981
Osborne CK, Von Hoff DD, Cowan JD, Sandbach J: Bisantrene, an active drug in patients with advanced breast cancer. Cancer Treat Rep 68:357–360, 1984
Yap H-Y, Yap B-S, Blumenschein GR, Barnes BC, Schell FC, Bodey GP: Bisantrene, an active drug in the treatment of metastatic breast cancer. Cancer Res 42:1402–1404, 1983
Myers JW, Von Hoff DD, Kuhn JG, Osborne CK, Sandbach JF, Polcelinko R: Anaphylactoid reactions associated with bisantrene infusions. Invest New Drugs 1:85–88, 1983
Author information
Authors and Affiliations
Additional information
This investigation was supported in part by the following PHS Cooperative Agreement grant numbers awarded by the National Cancer Institute, DHHS: CA-22433, CA-04920, CA-03096, CA-12644, CA-14028, CA-37981, CA-16385, CA-13238, CA-04915, CA-22411, CA-27057, CA-37445, CA-35178, CA-35995, CA-28862, CA-03389, CA-20319, CA-35117, CA-03396, CA-35438, CA-12213, CA-21116, CA-04919, CA-12014 and CA-32102.
Address for reprints: Southwest Oncology Group (SWOG-8203), Operations Office, 4450 Medical Drive, San Antonio, TX 78229, U.S.A.
Rights and permissions
About this article
Cite this article
Cowan, J.D., Osborne, C.K., Neidhart, J.A. et al. A randomized trial of doxorubicin, mitoxantrone and bisantrene in advanced breast cancer (A South West Oncology Group Study). Invest New Drugs 3, 149–152 (1985). https://doi.org/10.1007/BF00174162
Issue Date:
DOI: https://doi.org/10.1007/BF00174162